Key Takeaways

• Testosterone is a Schedule III controlled substance under federal law. Every physical location where testosterone is stored requires its own DEA registration tied to that address. A prescribing physician’s personal DEA registration does not cover facility storage — this is a common HRT clinic defect.
• California AB 82 (effective January 1, 2026) removed testosterone from CURES reporting. Testosterone remains Schedule III federally; California’s PDMP reporting requirement is what changed, not the underlying controlled-substance status. Do not read AB 82 as regulatory relaxation.
• California CPOM applies fully. HRT practice is the practice of medicine; the clinical entity has to be a physician-owned professional corporation under Cal. Corp. Code § 13401.5. LLCs cannot render medical services under § 17701.04(e).
• Non-testosterone hormones (estradiol, progesterone, DHEA, thyroid hormones, HCG) are prescription drugs but not controlled substances. Compounded bio-identical hormones sit in a distinct compliance layer around 503A patient-specific compounding and USP 797 sterile compounding.
• California B&P § 2290.5 permits Schedule III prescribing via real-time audio-video telehealth after establishing the provider-patient relationship. This is more permissive than federal Ryan Haight, but federal Ryan Haight (through the DEA’s Fourth Temporary Extension) still governs. Both apply.
• AB 890 104 NPs can prescribe testosterone and other Schedule III hormones with an active individual DEA registration and completion of the 4,600-hour transition-to-practice period.

Buying a Testosterone / HRT Clinic in California: A Non-Licensee Buyer’s Guide

Testosterone replacement therapy (TRT) and hormone replacement therapy (HRT) practices have expanded through cash-pay men’s-health clinics, functional-medicine and integrative-medicine practices, telehealth-forward direct-to-consumer platforms, and hybrid brick-and-mortar operations. Every one of them administers or dispenses controlled substances, prescription hormones, and (often) compounded formulations at scale. Every one of them is subject to California’s Corporate Practice of Medicine doctrine, the DEA’s registration and storage requirements, the Medical Board’s off-label prescribing standards, and — as of January 1, 2026, California’s Assembly Bill 82 amendment to the state’s Controlled Substances Utilization Review and Evaluation System (CURES).

Non-licensee buyers acquire California HRT practices through the friendly-PC + MSO structure. What makes HRT acquisitions distinct from other treatment-business categories is the specific combination of DEA facility-registration issues, hormone-specific supply-chain considerations, and 2026 California regulatory changes that a buyer’s diligence has to address. This post walks through those specifics. It sits under the buyer pillar for the CPOM Acquisition & Remediation cluster and is the companion to the ketamine and GLP-1 modality-specific buy posts.

The Three HRT Business Models a Buyer Sees

Model 1: Traditional men’s health / testosterone-focused practice. In-clinic evaluation, blood work, and initial testosterone prescription; ongoing management with periodic labs; often adjunctive medications (anastrozole, HCG, enclomiphene). Delivery by weekly or biweekly injection, either self-administered at home or in-clinic; pellets are an alternative delivery model with in-office insertion. Diligence emphasis: physician evaluation and monitoring standards, lab cadence, adjunctive medication protocols, DEA facility registration for stored injectable testosterone, and controlled-substance inventory reconciliation.

Model 2: Bio-identical HRT / integrative practice. Broader hormone panel — testosterone plus estradiol, progesterone, DHEA, thyroid, sometimes growth hormone or IGF-1 (which brings additional compliance layers). Compounded bio-identical formulations from 503A pharmacies. Often marketed for peri- and post-menopausal women, but also for men. Diligence emphasis: compounding pharmacy relationships and USP 797 compliance, DEA facility registration for stored injectable testosterone, marketing representations about “bio-identical” hormones (which is a marketing term, not a regulatory category), and the practice’s clinical evaluation and monitoring standards.

Model 3: Telehealth-forward TRT platform. Patient onboarding by digital intake and synchronous video evaluation; labs at Quest or Labcorp draw sites; prescriptions shipped from partnered pharmacies to the patient’s home. Some platforms operate their own DEA-registered dispensing infrastructure; others rely on pharmacy partners. Diligence emphasis: Ryan Haight Act compliance and the DEA Fourth Temporary Extension analysis, California B&P § 2290.5 workflow, multi-state licensure for platforms serving beyond California, pharmacy fulfillment relationships, and the practice’s clinical monitoring cadence (lab work at 3-month and 6-month intervals is the professional standard).

The three models are not mutually exclusive. Larger targets often combine them, and the acquisition analysis has to address each operational component separately.

DEA Registration: The Load-Bearing Compliance Layer

Every non-compliant HRT audit finding begins in the same place: the DEA registration mismatch.

The prescribing physician’s DEA registration authorizes the physician’s prescribing activity. It is tied to a registered address and includes the schedules the physician is authorized to prescribe (Schedule III is standard for HRT practices).

The facility DEA registration authorizes the storage of controlled substances at a specific physical location. It is a separate registration tied to that specific address. The prescribing physician’s personal registration does not cover the facility.

The distinction is where most non-compliant HRT clinics get caught. A practice stores injectable testosterone cypionate in a refrigerator at the office; the office does not have its own DEA registration; the physician’s personal DEA registration is on file. This is out of compliance with federal law. DEA civil monetary penalties for such violations can range from $1,000 to $25,000 per violation, and willful violations can be prosecuted criminally.

Buyer diligence. Confirm:

• The prescribing physician’s DEA registration is active, current, and includes Schedule III authorization.
• Every physical location where testosterone or other Schedule III substances are stored has its own DEA registration tied to that specific address.
• Multi-location practices have separate registrations for each location.
• Inventory records reconcile — testosterone in (from pharmacy or wholesale distributor), testosterone administered (patient records), testosterone remaining on hand, and testosterone disposed.
• Disposal records comply with the Secure and Responsible Drug Disposal Act framework.
• CURES posture reflects the AB 82 carve-out for testosterone (see next section).

What a red-flag answer looks like. “The doctor keeps testosterone at the office under his DEA number.” “The DEA registration was for a location we moved out of two years ago.” “Inventory? We track what we use; we don’t formally reconcile.”

AB 82 and the California CURES Carve-Out

California Assembly Bill 82 took effect January 1, 2026 and removed testosterone (and mifepristone) from CURES reporting requirements. The California Department of Justice must remove previously reported testosterone records from CURES no later than January 1, 2027.

What AB 82 changed.

• California prescribers and dispensing pharmacies no longer report testosterone prescriptions to CURES.
• Physicians reviewing a patient’s CURES history for controlled-substance oversight will not see testosterone prescriptions.
• Historical testosterone records will be removed from CURES by January 1, 2027.

What AB 82 did not change.

• Testosterone remains a Schedule III controlled substance under federal law and California state law.
• DEA registration and storage requirements remain in force.
• The prescribing physician’s clinical evaluation and monitoring standards under B&P § 2242 remain in force.
• California Medical Board and BRN oversight of testosterone prescribing remain in force.
• Federal audits (DEA, Medicare, TRICARE) remain possible.

The buyer’s diligence implication. AB 82 is a targeted PDMP reporting carve-out. It does not represent relaxation of controlled-substance oversight. A target that has read AB 82 as “we don’t need to track testosterone as carefully anymore” is a target with a compliance interpretation problem the buyer needs to address. A target whose EHR was auto-reporting testosterone to CURES prior to AB 82 needs to update its reporting configuration — over-reporting testosterone post-AB 82 can itself become a compliance issue.

Compounding and Non-Testosterone Hormones

HRT practices commonly rely on compounded formulations for testosterone (custom-dose injections, pellets), estradiol (creams, pellets, sublingual troches), progesterone (oral capsules, creams), DHEA, and thyroid preparations. Compounding raises two compliance layers:

503A patient-specific compounding. Legal when the compounded product is prescribed for an individual patient with a specific clinical need that a commercially available FDA-approved product does not address. The compounding pharmacy has to be state-licensed and USP 797-compliant for sterile products.

503B outsourcing facility compounding. Legal for FDA-registered outsourcing facilities compounding under specified conditions. Less common in traditional HRT practice, but relevant for larger platforms.

Buyer diligence on compounding relationships.

• Which specific formulations does the target rely on from compounding pharmacies?
• Is each compounding pharmacy state-licensed and, where applicable, FDA-registered as a 503B outsourcing facility?
• USP 797 compliance for sterile compounding (injectable testosterone, IM estradiol, injectable HCG)?
• Prescription documentation supporting each compounded product — patient-specific, medically necessary, not “essentially a copy” of a commercially available product?
• Any incidents involving contamination, adverse reactions, or product recalls?

HCG considerations. Human chorionic gonadotropin is used in many TRT practices adjunctively to preserve testicular function during testosterone therapy. Commercial HCG (Pregnyl and Novarel) is available but limited; many practices rely on compounded HCG from 503A pharmacies. Compounded HCG has been an FDA focus area; buyer diligence should confirm the target’s HCG sourcing and the medical-necessity documentation.

Peptide considerations. Peptide therapies (semaglutide-adjacent peptides, growth-hormone-releasing peptides, sexual-function peptides) have grown in HRT practices. Many peptides sit outside the FDA-approved framework entirely; some (specific to the compounded category) have been named in FDA enforcement actions. If the target includes peptide offerings, the FDA-approval status of each specific peptide is a diligence line worth surfacing.

CPOM and Ryan Haight for HRT Practices

CPOM. The clinical entity has to be a physician-owned professional corporation. LLCs cannot render medical services under Cal. Corp. Code § 17701.04(e). HRT practices operating through LLCs have the same structural defect as any other California treatment business operating that way, regardless of the “wellness” or “men’s health” marketing framing.

Ryan Haight and B&P § 2290.5. For telehealth-forward TRT practices, federal Ryan Haight and California B&P § 2290.5 both apply.

The DEA’s Fourth Temporary Extension — published December 31, 2025, effective through December 31, 2026, allows a DEA-registered practitioner to prescribe Schedule III controlled substances (including testosterone) via audio-video telemedicine without a prior in-person evaluation, provided all other federal and state requirements are met.

California B&P § 2290.5 permits Schedule III prescribing via real-time audio-video telehealth after establishing the provider-patient relationship, and the California Medical Board and BRN recognize synchronous telehealth encounters as a valid basis for initiating controlled-substance prescriptions.

The two frameworks operate together. A telehealth TRT platform serving California patients has to comply with both. The federal framework is on a fixed expiration schedule (December 31, 2026 as of drafting); the California framework is stable. Practices structured entirely around federal Ryan Haight flexibility have business-continuity exposure if permanent DEA rules require in-person evaluation.

NP prescribing. AB 890 104 NPs (full-practice authority NPs who have completed the 4,600-hour transition-to-practice period) can prescribe testosterone and other Schedule III hormones with an active individual DEA registration. Traditional NPs and PAs may prescribe within a delegation framework under standardized procedures and physician oversight.

Marketing and Clinical-Standard Considerations

TRT and HRT marketing has been a recurring focus of state medical board and FTC scrutiny. Common exposure patterns:

“Treating the number” marketing. Marketing that positions any adult male with testosterone below a particular threshold as a candidate for TRT, without appropriate clinical evaluation, is one of the common Medical Board substandard-care findings. The prescribing standard requires a clinical diagnosis (typically documented hypogonadism, secondary hypogonadism, or an equivalent clinical indication) supported by symptoms, examination, and laboratory findings — not just a laboratory value.

Lab-cadence marketing. Marketing that treats initial labs as sufficient for ongoing prescribing, without regular follow-up labs, deviates from professional standards. Pre-treatment labs, 3-month follow-up labs, and 6-month follow-up labs are the professional standard, and gaps in this cadence are diligence findings.

Adverse-event risk framing. TRT carries meaningful adverse-event risks (polycythemia, cardiovascular risk signals, prostate concerns, fertility impact). Marketing that minimizes or omits these risks is a false-advertising exposure category under B&P § 17500.

Anti-aging framing. Marketing that positions TRT as anti-aging therapy without a specific clinical indication is generally outside the accepted clinical framework and creates both regulatory and payor exposure.

Buyer diligence should audit the target’s marketing history and identify the marketing rebuild scope for post-closing operations.

When to Bring Counsel Into an HRT Acquisition

Before the LOI is signed. HRT is a category where the DEA facility-registration issue is common enough that buyer’s counsel routinely finds targets operating without appropriate facility registrations, and where the AB 82 CURES change has created interpretation confusion in the industry. Pre-LOI structural counsel is where the deal is either built for the current framework or set up to inherit the seller’s DEA, CPOM, and marketing exposure.

Bay Legal, PC represents non-licensee buyers of California HRT and TRT practices through pre-LOI structural counsel, DEA and CPOM diligence, and deal documentation. Call (650) 668-8000 or schedule a consultation at baylegal.com/contact.

Frequently Asked Questions

Can a non-doctor buy a TRT or HRT clinic in California?

Yes, through the friendly-PC + MSO structure. A licensed physician acquires the clinical assets into a newly formed professional corporation. The buyer’s management entity acquires the non-clinical assets and provides services to the PC under a Management Services Agreement. Direct purchase of the seller’s LLC and continued operation through the LLC is not a compliant path.

Does my physician’s DEA registration cover our clinic’s testosterone storage?

No. The prescribing physician’s personal DEA registration authorizes prescribing activity but does not cover facility storage of controlled substances. Every physical location where testosterone or other Schedule III substances are stored requires its own DEA registration tied to that specific address. Multi-location practices need separate registrations for each location. This is a common diligence finding — practices that store testosterone under only the physician’s personal registration are operating outside federal law.

Did AB 82 make testosterone easier to prescribe in California?

No. AB 82, effective January 1, 2026, removed testosterone from CURES (California’s PDMP) reporting requirements. Testosterone remains a Schedule III controlled substance federally and in California. DEA registration and storage requirements remain in force. The prescribing physician’s clinical evaluation and monitoring standards under B&P § 2242 remain in force. AB 82 is a targeted PDMP reporting carve-out, not a relaxation of controlled-substance oversight.

Can nurse practitioners prescribe testosterone in California?

Yes, subject to specific requirements. California’s AB 890 104 NP category (full-practice authority NPs who have completed the 4,600-hour transition-to-practice period) may prescribe Schedule III controlled substances including testosterone, provided the NP holds an active individual DEA registration. Traditional NPs operating under standardized procedures with a collaborating physician can also participate in testosterone prescribing within the standardized-procedures framework. Diligence should confirm each prescribing NP’s practice-authority category and DEA registration.

What is the biggest single diligence finding in HRT acquisitions?

DEA facility-registration mismatch — practices storing testosterone at office locations that lack their own DEA registrations, relying on the physician’s personal DEA registration. This is common enough that buyer’s counsel routinely finds it. The remediation is straightforward (apply for facility DEA registration for each storage location), but the historical exposure, for the period the practice operated without appropriate facility registration, is a diligence line the buyer’s deal documents need to allocate.

Talk to a California HRT Acquisition Attorney

Bay Legal, PC represents non-licensee buyers of California TRT and HRT practices. Whether the target operates as a traditional men’s health clinic, a bio-identical HRT practice, a telehealth platform, or a hybrid, we can help you structure the deal for CPOM, DEA, and 2026 California regulatory framework compliance. Call (650) 668-8000 or schedule a consultation at baylegal.com/contact.